Although chemotherapy using single-agent immune checkpoint inhibitor (ICI) is considered not effective in the noninflamed HCC, a combination of ICI and anti-vascular endothelial growth factor (VEGF) antibodies can be effective in such an immunosuppressive tumor microenvironment [2,3]. This evidence concerns the gene VEGFA and neoplasm.